Skip to Main Content

Paper Details

Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model.
J Urol
4
2023

Datasets

Release 1.2